Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Knight Therapeutics Inc (GUD.TO)

Knight Therapeutics Inc (GUD.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 575,878
  • Shares Outstanding, K 99,289
  • Annual Sales, $ 371,304 K
  • Annual Income, $ 4,332 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta -0.01
  • Price/Sales 1.43
  • Price/Cash Flow 16.36
  • Price/Book 0.75

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.00
  • Number of Estimates 2
  • High Estimate 0.01
  • Low Estimate 0.00
  • Prior Year 0.11
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.66 +4.42%
on 01/14/26
6.11 -3.27%
on 01/13/26
unch (unch)
since 01/02/26
3-Month
5.66 +4.42%
on 01/14/26
6.27 -5.74%
on 11/13/25
+0.07 (+1.20%)
since 10/31/25
52-Week
5.29 +11.72%
on 02/03/25
6.55 -9.77%
on 08/29/25
+0.37 (+6.68%)
since 01/31/25

Most Recent Stories

More News
Knight Therapeutics Announces Health Canada Approval for WYNZORA® to Treat Psoriasis Vulgaris

MONTREAL, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approved ...

GUD.TO : 5.91 (+1.90%)
Stocks in play: Knight Therapeutics Inc.

Today reported financial results for its third quarter ended September 30, 2025. Revenues were $121,548, ...

GUD.TO : 5.91 (+1.90%)
Knight Therapeutics Reports Third Quarter 2025 Results

Achieved record-high quarterly revenues, Adjusted EBITDA 1 and Adjusted EBITDA per share 1 since inception Increased 2025 financial guidance MONTREAL, Nov. 06, 2025 (GLOBE...

GUD.TO : 5.91 (+1.90%)
Knight Announces Closing of US$100 Million Revolving Credit Facility

MONTREAL, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, announced today that it has closed...

GUD.TO : 5.91 (+1.90%)
Knight Therapeutics Announces Launch of JORNAY PM™ in Canada

MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of JORNAY PM™ (methylphenidate...

COLL : 47.11 (+2.59%)
GUD.TO : 5.91 (+1.90%)
Notice of Knight Therapeutics' Third Quarter 2025 Results Conference Call

MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2025 financial...

GUD.TO : 5.91 (+1.90%)
Knight Therapeutics Announces Approval and Launch of MINJUVI® (tafasitamab) in Argentina

MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Laboratorio...

GUD.TO : 5.91 (+1.90%)
Knight Therapeutics Announces Relaunch of ORGOVYX® in Canada

MONTREAL, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has relaunched ORGOVYX ®...

GUD.TO : 5.91 (+1.90%)
Knight Therapeutics Announces Relaunch of MYFEMBREE® in Canada

MONTREAL, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has relaunched MYFEMBREE...

GUD.TO : 5.91 (+1.90%)
Knight Therapeutics Inc. places No. 384 on The Globe and Mail's seventh annual ranking of Canada's Top Growing Companies

MONTREAL, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) is pleased to announce it has ranked No. 384 on the 2025 Report on Business magazine’s...

GUD.TO : 5.91 (+1.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin...

See More

Key Turning Points

3rd Resistance Point 6.17
2nd Resistance Point 6.06
1st Resistance Point 5.98
Last Price 5.91
1st Support Level 5.79
2nd Support Level 5.68
3rd Support Level 5.60

See More

52-Week High 6.55
Fibonacci 61.8% 6.07
Fibonacci 50% 5.92
Last Price 5.91
Fibonacci 38.2% 5.77
52-Week Low 5.29

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar